The global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is estimated to have a significant CAGR during the forecast period. The market is mainly driven due to increasing prevalence of respiratory diseases such as asthma and COPD across the globe coupled with growing R&D for the development of new drugs. Asthma is one of the major respiratory diseases that has affected almost every major economy across the globe. During an asthma attack, the lining of the bronchial tubes swells, which results in narrowing of airways and reduced flow of air through lungs. According to the Global Asthma Report 2018, Asthma affects 339 million people across all regions. It is one of the major causes of death and disability as nearly 1,000 people lost their lives each day due to asthma. Moreover, it was estimated that 3.17 million mortalities were caused due to COPD in 2015, which is 5% of all the mortalities across the globe in 2016. Therefore significant number of asthma and COPD contribute in the market.

Segmental Outlook  

The global asthma and COPD drugs market is segmented based on disease type and application. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have considerable share owing to the high demand of drug treatment in asthma coupled with growing asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. 

 Global asthma and COPD drugs Market Share by Disease Type, 2019(%)

Global asthma and COPD drugs Market to be driven by Asthma 

The Asthma segment held a considerable share in the market owing to the growing prevalence of asthma across the globe. According to the Global Asthma Report 2018, Asthma affects 339 million people across all regions. It is one of the major causes of death and disability as nearly 1,000 people lost their lives each day due to asthma. It is ranked 28th among the major causes of disease burden, as per disability-adjusted life years (DALYs). As per the report, inhaled therapy is essential to treat chronic and acute asthma and the MDI along with a spacer is considered as an optimal delivery therapy among children. Furthermore, the companies are launching new asthma drugs for more affordable and effective treatment of people with asthma. For instance, in April 2017, Teva Pharmaceutical Industries Ltd. launched AirDuo RespiClick (salmeterol and fluticasone propionate) inhalation powder and its authorized generic to treat patients aged 12 years and over. It is a fixed-dose integration of asthma therapies comprised of an inhaled corticosteroids (ICS) and a long-acting beta2-adrenergic agonist (LABA). 

Regional Outlook 

Geographically, the global asthma and COPD drugs market is further classified into North America, Europe, Asia-Pacific and the Rest of the World. Asia-Pacific is estimated to have considerable market growth in the global market during the forecast period. The market growth in the region is increasing owing to the high prevalence of asthma and COPD coupled with increasing number of smokers in the region. The major countries which will have a significant market share during the forecast period are India, China, and Japan. Apart from these nations, South Korea and Singapore are some of the other major economies where considerable growth would be observed.

Global asthma and COPD drugs Market Growth, by Region 2020-2026

North America to hold a considerable share in the global asthma and COPD drugs market

Geographically, North America is projected to hold a significant market share in the global asthma and COPD drugs market. Major economies which are anticipated to contribute to the North America market are the US and Canada. The growth of the market  in the US is mainly driven by factors such as the growing prevalence of respiratory diseases such as asthma, and COPD. Asthma is chronic inflammation of the lung airways that causes breathlessness and coughing. The number of people with asthma grows every year in the US. According to CDC, there are around 26 million asthma patients in the US, among which, nearly 18.9 million are adults and 7.1 million are children. Moreover, the prevalence of asthma in children is nearly 9.4% which is higher than that of adults accounting to around 7.7%, and higher in females nearly 9.2% than in males accounting to 7% of total asthma patients. This is one of the primary reasons for the high growth rate of the market in this region. 

Market Players Outlook

The key players in the asthma and COPD drugs market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Grifols, S.A., GlaxoSmithKline PLC, Pfizer Inc.,  and others. These market players adopt various strategies such as product launch, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global asthma and COPD drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.